NRM-823 is a first-in-class, bispecific T-cell engager (TCE) developed by Normunity designed to redirect T cells to recognize and destroy cancer cells in patients with locally advanced or metastatic solid tumors.

Overview and Mechanism

• Target: Binds to a proprietary, highly tumor-specific "Immuno-smart" cell-surface target that is co-opted by cancer cells to drive local immune suppression, while remaining absent in normal systemic tissues.
• Function: Acts as a bridge between endogenous T cells and tumor cells, inducing potent T cell-mediated cytotoxicity.
• Platform Origin: Developed through an ongoing academic-biotech partnership with the Lieping Chen laboratory at the Yale School of Medicine.